What cancers does elacestrant treat?

Elacestrant is an oral selective estrogen receptor degrader (SERD) specifically indicated for the treatment of patients with advanced or metastatic breast cancer, especially those who are estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-). The drug's primary indications include postmenopausal women and adult men whose disease has progressed after at least one type of endocrine therapy.

During the treatment of advanced breast cancer, the estrogen receptor (ER) is a key factor driving the growth of cancer cells. Estrogen promotes the proliferation and spread of cancer cells by binding to the ER. Traditional endocrine therapies, such as aromatase inhibitors or tamoxifen, aim to block estrogen production or binding to receptors, thereby controlling tumor growth. However, as treatment progresses, some patients' cancer cells will develop ESR1 gene mutations, which changes the tumor's dependence on estrogen signals, causing traditional treatments to fail and the disease to progress.

Elastrast uses a unique mechanism to precisely attack this type of drug-resistant lesions. It not only blocks the binding of estrogen to receptors, but also induces receptor degradation and reduces the number of available estrogen receptors on the surface of cancer cells, thereby effectively inhibiting the estrogen signaling pathway. This dual mechanism of action enables elastran to show good efficacy in the treatment of ER+HER2- advanced breast cancer patients carrying ESR1 mutations, especially after failure of other endocrine treatments.

Patients suitable for this drug have usually received a variety of regimens includingCDK4/6 inhibitors combined with endocrine therapy, but need to seek new treatment strategies due to disease progression. Elastran provides a new option for these patients, which can delay further progression of the disease and improve the patient's quality of life. Its oral administration method also facilitates long-term management and improves patient treatment compliance.

References:https://www.drugs.com/mtm/elacestrant.html